# Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

> **NCT06070012** · PHASE2 · RECRUITING · sponsor: **Diwakar Davar** · enrollment: 44 (estimated)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Tebentafusp

## Key facts

- **NCT ID:** NCT06070012
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2028-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06070012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06070012, "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06070012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*